REG - Venture Life Group - Grant of Options and PDMR Dealing

Venture LifeAnnouncement

22/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220222:nRSV3405Ca&default-theme=true

RNS Number : 3405C  Venture Life Group PLC  22 February 2022

22(nd) February 2022

 

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Group")

Grant of Options

 

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, has, on the recommendation
of the Company's Remuneration Committee, issued options over 300,000 ordinary
shares of 0.3 pence each in the Company to Daniel Wells, Chief Financial
Officer. Mr Wells has been awarded 300,000 unapproved share options under the
Company's Share Option Plan, with an exercise price of 43.0 pence per share,
being the closing mid-market price on 21(st) February 2022. The vesting of
these options is subject to continuing employment and the satisfaction of
performance conditions based on profitability and TSR targets. The options
become exercisable on 31(st) March 2025.

As a results of the issue of these share options, Daniel Wells holds options
over a total of 445,349 ordinary shares in the Company.

 

 

For further information, please contact:

 

 Venture Life Group PLC                              +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cenkos Securities plc (Nomad and Joint Broker)      +44 (0) 20 7397 8900
 Michael Johnson/Russell Kerr (Sales)

 Stephen Keys/Camilla Hume (Corporate Finance)

 Singer Capital markets (Joint Broker)               +44 (0) 20 7496 3000
 Jonathan Dighe (Sales)

 Shaun Dobson/Alaina Wong (Corporate Finance)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The Netherlands and
Sweden, the Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Active range in the
area of women's intimate healthcare, the Lift and Glucogel product ranges for
hypoglycaemia, products for fungal infections and proctology, and
dermo-cosmetics for addressing the signs of ageing. Its products are sold in
over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

 

The Company makes the following disclosures in accordance with article 19(3)
of the Market Abuse Regulation:

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Daniel Wells

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Venture Life Group plc

 b)   LEI                                                          213800S8CZUPLAB2KC70

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.3p each in Venture Life Group plc

      Identification code

                                                                   GB00BFPM8908

 b)   Nature of the transaction                                    Grant of new options for ordinary shares

 c)   Price(s) and volume(s)

Price(s)           Volume(s)

                                                                   Exercise Price -   300,000

                                                                   43.0p per option

 

 d)   Aggregated information                                       n/a

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      22(nd) February 2022

 f)   Place of the transaction                                     n/a

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

n/a

 

 

 

 

 

 

e)

 

Date of the transaction

 

 

22(nd) February 2022

f)

 

Place of the transaction

 

 

n/a

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUAOBRUKUUUAR